title: Angiotensinogen M235T genotype predicts progression in chronic renal allograft dysfunction.
abstract: BACKGROUND
  Genotypes of the renin-angiotensin system have been implicated in essential hypertension and in progression of native kidney diseases, but gene effects on progression in chronic renal allograft dysfunction are unclear.
  
  
  METHODS
  To examine gene effects on long-term renal allograft function, we conducted a prospective cohort study of 210 nondiabetic renal allograft recipients younger than 36 years of age who underwent transplantation between 1980 and 1993 and were followed up through 1999. All grafts survived more than 1 year and all subjects received cyclosporine-based immunosuppression. DNA was analyzed by polymerase chain reaction for the angiotensin-converting enzyme insertion/deletion and angiotensinogen (AGT) M235T polymorphisms. Linear regression multivariate modeling of the slope of the inverse creatinine-versus-time, survival analyses for time-to-sustained doubling of baseline serum creatinine, time-to-graft loss, and a composite endpoint including patient death were performed.
  
  
  RESULTS
  Mean follow-up time was 8.4+/-3 years. Genotype frequencies for each marker system did not deviate significantly from the Hardy-Weinberg equilibrium. The slope of the inverse creatinine-versus-time for AGT 235T/T and M/T was significantly increased compared with M/M ( <0.0001). The AGT 235T/T genotype was also associated with a shorter time-to-sustained doubling of serum creatinine ( =0.001). When subjects were divided into quartiles based on slope magnitude, the frequency of the AGT 235T/T genotype was overrepresented in the fastest progressing group compared with the slowest ( =0.001). The AGT 235T/T genotype was also associated with shorter time-to-graft loss ( =0.007) and the composite endpoint ( =0.001).
  
  
  CONCLUSIONS
  The AGT 235 T allele independently influences long-term decline in renal allograft function.
authors.affiliation: Department of Medicine, University of Toronto, Toronto, Ontario, Canada. prasadr@smh.toronto.on.ca.
authors.forename: G V Ramesh
authors.initials: GV
authors.lastname: Prasad
authors.forename: Dushanthi
authors.initials: D
authors.lastname: Pinnaduwage
authors.forename: Robert K
authors.initials: RK
authors.lastname: Parkes
authors.forename: Julian
authors.initials: J
authors.lastname: Midgley
authors.forename: J Williamson
authors.initials: JW
authors.lastname: Balfe
authors.forename: Robert A
authors.initials: RA
authors.lastname: Hegele
authors.forename: Shelley B
authors.initials: SB
authors.lastname: Bull
authors.forename: Edward H
authors.initials: EH
authors.lastname: Cole
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Logan
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000808:Angiotensinogen / Q000235:genetics*; D002648:Child; D002675:Child, Preschool; D018450:Disease Progression; D005838:Genotype; D006085:Graft Survival; D006801:Humans; D007674:Kidney Diseases / Q000235:genetics*; D016030:Kidney Transplantation / Q000009:adverse effects*; D008875:Middle Aged; D014184:Transplantation, Homologous
chemical_list: D000808:Angiotensinogen